2025
Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).
Kashima S, Xu W, Canniff J, Saliby R, Sun M, Lee G, Machaalani M, Signoretti S, McGregor B, McKay R, Choueiri T, Braun D. Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 562-562. DOI: 10.1200/jco.2025.43.5_suppl.562.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaRenal cell carcinoma patientsICI-based therapyNon-respondersPatients treated with ICI monotherapyResistance to immune checkpoint inhibitorsHLA-BICI respondersAdvanced renal cell carcinomaImmune cells to tumorsTGF-B pathwayTreatment evolutionCells to tumorsSustained immune activationPlasma samplesProfiling of plasma samplesCornerstone of treatmentPaired samplesPlasma proteomic analysisAssociated with responseAnti-tumor inflammationICI monotherapyInvestigated plasma proteinsCheckpoint inhibitors
2024
A kidney-hypothalamus axis promotes compensatory glucose production in response to glycosuria
Faniyan T, Zhang X, Morgan D, Robles J, Bathina S, Brookes P, Rahmouni K, Perry R, Chhabra K. A kidney-hypothalamus axis promotes compensatory glucose production in response to glycosuria. ELife 2024, 12 DOI: 10.7554/elife.91540.4.Peer-Reviewed Original ResearchGlucose productionEndogenous glucose productionReabsorption of nutrientsLoss of glucoseHypothalamic-pituitary-adrenal axisNormal energy supplyProteomic analysisCompensatory increaseAfferent renal nervesAfferent renal denervationPlasma proteomic analysisDefense mechanismsAcute phase proteinsRenal denervationKO miceSGLT2 inhibitorsKnockout miceRenal nervesAfferent nervesEfficiency of drugsBody's defense mechanismsGlycosuriaGlucosePhase proteinsTreat hyperglycemia
2020
638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis
Abdel-Wahab N, Diab A, Katayama H, Kim S, Hanash S, Suarez-Almazor M. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a674-a674. DOI: 10.1136/jitc-2020-sitc2020.0638.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsRenal cell carcinomaNon-small cell lung carcinomaPlasma proteomic analysisStatistically significant differenceCheckpoint inhibitorsCell carcinomaAdverse eventsBiomarkers of immune-related adverse eventsDevelopment of immune-related adverse eventsPatients treated with immune checkpoint inhibitorsAnti-programmed cell death 1Immune checkpoint inhibitor initiationImmune checkpoint inhibitor treatmentResponse to ICI therapyNon-small cell lung cancerBlood drawThe University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterAnti-PD1 treatmentAnti-tumor immunityMD Anderson Cancer CenterCell death 1Inflammation of lung tissue21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Harel M, Lahav C, Jacob E, Issler E, Bar H, Dicker A, Sharon O, Bacchiocchi A, Halaban R, Sznol M, Shaked Y. 21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients. Journal For ImmunoTherapy Of Cancer 2020, 8: a11-a12. DOI: 10.1136/jitc-2020-sitc2020.0021.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMelanoma patientsClinical outcomesHost responseNon-small cell lung cancerCell lung cancerNon-responder groupPlasma samplesPro-metastatic effectsAnti-tumor activityPredictive biomarker discoveryProteomic profilingPlasma proteomic analysisAnti-cancer therapyICI therapyCheckpoint inhibitorsRECIST criteriaLung cancerTreatment modalitiesMechanisms of resistanceIndependent cohortPatientsTumor progressionPredictive signatureImmunotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply